Skip to main content
. 2014 Apr 3;8:415–422. doi: 10.2147/PPA.S53140

Figure 1.

Figure 1

Mean percentage of patients prescribed individual DMTs, as reported by neurologists.

Note: *Includes patients on natalimumab (6.6%) and other medications (azathioprine, cladribine, cyclophosphamide, daclizumab, intravenous immunoglobulin, methotrexate, mycophenolate mofetil, naltrexone, rituximab, corticosteroids, teriflunimide [1.1% combined]).

Abbreviations: MS, multiple sclerosis; IM, intramuscular; IFN, interferon; SC, subcutaneous; DMTs, disease-modifying therapies.